North America Overactive Bladder Treatment Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Pharmacotherapy (Anticholinergics, Mirabegron, Botox, Neurostimulation, and Intravesical Instillation) and Disease Type (Idiopathic Overactive

North America Overactive Bladder Treatment Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Pharmacotherapy (Anticholinergics, Mirabegron, Botox, Neurostimulation, and Intravesical Instillation) and Disease Type (Idiopathic Overactive Bladder and Neurogenic Bladder)

The North America overactive bladder treatment market is expected to grow from US$ 1,682.29 million in 2022 to US$ 2,059.43 million by 2028; it is estimated to grow at a CAGR of 3.4% from 2022 to 2028.

Increase in Prevalence of Urinary Incontinence Drives North America Overactive Bladder Treatment Market

Urinary incontinence is the loss of bladder control caused due to the improper functioning of the muscles and nerves that control the passage of urine through the bladder. Stress incontinence and urge incontinence are the two common types of urinary incontinence affecting women, wherein the latter is also known as overactive bladder. As per the Office on Women's Health, a division of the US Department of Health and Human Services, the prevalence of incontinence in women is twice as in men, and aging, pregnancy, childbirth, and menopause can be the key factors leading to this condition in women. A few other factors affecting the function of muscles and nerves include overweight, constipation, or pelvic surgeries. As stated by the North American Menopause Society (NAMS), in the US, the prevalence of urinary incontinence was 17.1% among women aged 20 years or more and 38% in women aged 60 years and older in 2021. Urinary incontinence can affect women at any age; however, it is more common in older women due to hormonal changes during menopause. Thus, the surge in urinary related diseases is directly driving the North America overactive bladder treatment market .

North America Overactive Bladder Treatment Market Overview

The North America overactive bladder treatment market is segmented into the US, Canada, and Mexico. North America accounted for the largest share of the overactive bladder treatment market in 2021, owing to the increase in the geriatric population and prevalence of overactive diseases and Parkinson’s Disease. According to Parkinson’s Foundation, ~1 million people in the US are suffering from Parkinson’s Disease, and it is likely to reach 1.2 million by 2030. Although overactive bladder can occur at any age, it is quite prevalent in the population aged above 60 years. As per the Administration for Community Living, 16% of the US population was aged 65 and above in 2019, and it is expected to reach ~21.6% by 2040. The Population Reference Bureau (PRB) stated that the number of Americans aged 65 and older is projected to nearly double from 52 million in 2018 to 95 million by 2060. According to Cleveland Clinic Organization, ~33 million adults in the US are affected by an overactive bladder. Further, an article by John Wiley & Sons, Inc. stated that ~17% of the US population suffers from this condition. Thus, the demand for overactive bladder treatment is increasing across the region.

North America Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US$ Million)

North America Overactive Bladder Treatment Market Segmentation

The North America overactive bladder treatment market is segmented based on pharmacotherapy, disease type, and country.

Based on pharmacotherapy, the North America overactive bladder treatment market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment registered the largest share of the market in 2022.

Based on disease type, the North America overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held a larger share of the market in 2022.

Based on country, the North America overactive bladder treatment market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022.

AbbVie Inc; Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Axonics Modulation Technologies, Inc; Colorado Urology Associates, PLLC; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the North America overactive bladder treatment market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America overactive bladder treatment market
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the North America overactive bladder treatment market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the overactive bladder treatment market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution